| MeSH term | MeSH ID | Detail |
|---|---|---|
| Tuberculosis, Pulmonary | D014397 | 18 associated lipids |
| Bronchial Spasm | D001986 | 18 associated lipids |
| Peptic Ulcer | D010437 | 19 associated lipids |
| Drug Hypersensitivity | D004342 | 20 associated lipids |
| Gastrointestinal Diseases | D005767 | 20 associated lipids |
| Tuberculosis | D014376 | 20 associated lipids |
| Myocardial Infarction | D009203 | 21 associated lipids |
| Helicobacter Infections | D016481 | 21 associated lipids |
| Bacterial Infections | D001424 | 21 associated lipids |
| Periodontitis | D010518 | 22 associated lipids |
clarithromycin
clarithromycin is a lipid of Polyketides (PK) class. Clarithromycin is associated with abnormalities such as Helicobacter Pylori Infection, Infection, Coinfection, Gastritis and Peptic Ulcer. The involved functions are known as Point Mutation, Increased Sensitivy, Bacterial resistance, urease activity and Mutation. Clarithromycin often locates in Blood, Gastric mucosa, Biopsy sample, Respiratory System and Entire gastrointestinal tract. The associated genes with clarithromycin are Genes, rRNA, rRNA Operon, Genome, HM13 gene and GDF15 gene. The related lipids are 9,11-linoleic acid, Steroids, Lysophosphatidylcholines, Lipopolysaccharides and 4-hydroxycholesterol. The related experimental models are Mouse Model, Knock-out and Experimental Pneumococcal Meningitis.
Cross Reference
Introduction
To understand associated biological information of clarithromycin, we collected biological information of abnormalities, associated pathways, cellular/molecular locations, biological functions, related genes/proteins, lipids and common seen animal/experimental models with organized paragraphs from literatures.
What diseases are associated with clarithromycin?
clarithromycin is suspected in Infection, Helicobacter Pylori Infection, Pneumonia, Respiratory Tract Infections, PARKINSON DISEASE, LATE-ONSET, Community acquired pneumonia and other diseases in descending order of the highest number of associated sentences.
Related references are mostly published in these journals:
- Antimicrob. Agents Chemother. (63)
- J. Antimicrob. Chemother. (56)
- J. Clin. Microbiol. (39)
- Others (258)
| Disease | Cross reference | Weighted score | Related literature |
|---|
Loading... please refresh the page if content is not showing up.
Possible diseases from mapped MeSH terms on references
We collected disease MeSH terms mapped to the references associated with clarithromycin
PubChem Associated disorders and diseases
What pathways are associated with clarithromycin
There are no associated biomedical information in the current reference collection.
PubChem Biomolecular Interactions and Pathways
Link to PubChem Biomolecular Interactions and PathwaysWhat cellular locations are associated with clarithromycin?
Visualization in cellular structure
Associated locations are in red color. Not associated locations are in black.
Related references are published most in these journals:
- J. Antimicrob. Chemother. (25)
- Antimicrob. Agents Chemother. (20)
- J. Clin. Microbiol. (9)
- Others (66)
| Location | Cross reference | Weighted score | Related literatures |
|---|
Loading... please refresh the page if content is not showing up.
What functions are associated with clarithromycin?
Related references are published most in these journals:
| Function | Cross reference | Weighted score | Related literatures |
|---|
What lipids are associated with clarithromycin?
Related references are published most in these journals:
- Antimicrob. Agents Chemother. (5)
- Drug Metab. Dispos. (1)
- FEMS Immunol. Med. Microbiol. (1)
- Others (5)
| Lipid concept | Cross reference | Weighted score | Related literatures |
|---|
Loading... please refresh the page if content is not showing up.
What genes are associated with clarithromycin?
Related references are published most in these journals:
- J. Antimicrob. Chemother. (20)
- Antimicrob. Agents Chemother. (17)
- J. Clin. Microbiol. (13)
- Others (57)
| Gene | Cross reference | Weighted score | Related literatures |
|---|
What common seen animal models are associated with clarithromycin?
Mouse Model
Mouse Model are used in the study 'Inflammation provoked by Mycoplasma pneumoniae extract: implications for combination treatment with clarithromycin and dexamethasone.' (Hirao S et al., 2011), Mouse Model are used in the study 'Tolerance and pharmacokinetic interactions of rifabutin and clarithromycin in human immunodeficiency virus-infected volunteers.' (Hafner R et al., 1998), Mouse Model are used in the study 'Clarithromycin attenuates mastectomy-induced acute inflammatory response.' (Chow LW et al., 2000) and Mouse Model are used in the study 'In vitro and in vivo influence of adjunct clarithromycin on the treatment of mucoid Pseudomonas aeruginosa.' (Bui KQ et al., 2000).
Knock-out
Knock-out are used in the study 'Intrinsic macrolide resistance in Mycobacterium smegmatis is conferred by a novel erm gene, erm(38).' (Nash KA, 2003).
Experimental Pneumococcal Meningitis
Experimental Pneumococcal Meningitis are used in the study 'Failure of treatment for chronic Mycobacterium abscessus meningitis despite adequate clarithromycin levels in cerebrospinal fluid.' (Maniu CV et al., 2001).
Related references are published most in these journals:
| Model | Cross reference | Weighted score | Related literatures |
|---|
Loading... please refresh the page if content is not showing up.
NCBI Entrez Crosslinks
All references with clarithromycin
Download all related citations| Authors | Title | Published | Journal | PubMed Link |
|---|---|---|---|---|
| Miehlke S et al. | Treatment of Helicobacter pylori infection. | 2001 | Semin. Gastrointest. Dis. | pmid:11478749 |
| Terkeltaub RA | Colchicine update: 2008. | 2009 | Semin. Arthritis Rheum. | pmid:18973929 |
| Moskowitz RW et al. | Open-label study of clarithromycin in patients with undifferentiated connective tissue disease. | 2006 | Semin. Arthritis Rheum. | pmid:17023256 |
| Mateo L et al. | Mycobacterium chelonae tenosynovitis of the hand. | 2004 | Semin. Arthritis Rheum. | pmid:15609266 |
| Liang J et al. | [Analysis of the key intermediates for the regioselectivity control in the methylation of the manufacture of clarithromycin by reversed-phase high performance liquid chromatography]. | 2004 | Se Pu | pmid:15712906 |
| Velu PP et al. | Pulmonary Mycobacterium marinum infection: 'fish tank granuloma' of the lung. | 2016 | Scott Med J | pmid:27872397 |
| Cadwgan AM et al. | Neisseria meningitidis W135 pneumonia with sepicaemia in a nonogenarian. | 1998 | Scott Med J | pmid:9854302 |
| Isidori M et al. | Toxic and genotoxic evaluation of six antibiotics on non-target organisms. | 2005 | Sci. Total Environ. | pmid:15993685 |
| Göbel A et al. | Fate of sulfonamides, macrolides, and trimethoprim in different wastewater treatment technologies. | 2007 | Sci. Total Environ. | pmid:17126383 |
| Buchicchio A et al. | Biodegradation of carbamazepine and clarithromycin by Trichoderma harzianum and Pleurotus ostreatus investigated by liquid chromatography - high-resolution tandem mass spectrometry (FTICR MS-IRMPD). | 2016 | Sci. Total Environ. | pmid:27039063 |
| Al Aukidy M et al. | Monitoring release of pharmaceutical compounds: occurrence and environmental risk assessment of two WWTP effluents and their receiving bodies in the Po Valley, Italy. | 2012 | Sci. Total Environ. | pmid:22967493 |
| Topp E et al. | Reduced persistence of the macrolide antibiotics erythromycin, clarithromycin and azithromycin in agricultural soil following several years of exposure in the field. | 2016 | Sci. Total Environ. | pmid:27096634 |
| Spongberg AL and Witter JD | Pharmaceutical compounds in the wastewater process stream in Northwest Ohio. | 2008 | Sci. Total Environ. | pmid:18396321 |
| Feng L et al. | Removal of antibiotics during the anaerobic digestion of pig manure. | 2017 | Sci. Total Environ. | pmid:28628813 |
| Karaolia P et al. | Reduction of clarithromycin and sulfamethoxazole-resistant Enterococcus by pilot-scale solar-driven Fenton oxidation. | 2014 | Sci. Total Environ. | pmid:24012892 |
| Ratzinger F et al. | Azithromycin suppresses CD4(+) T-cell activation by direct modulation of mTOR activity. | 2014 | Sci Rep | pmid:25500904 |
| Bruhn DF et al. | In vitro and in vivo Evaluation of Synergism between Anti-Tubercular Spectinamides and Non-Classical Tuberculosis Antibiotics. | 2015 | Sci Rep | pmid:26365087 |
| Vliegenthart AD et al. | Comprehensive microRNA profiling in acetaminophen toxicity identifies novel circulating biomarkers for human liver and kidney injury. | 2015 | Sci Rep | pmid:26489516 |
| Arora S et al. | Amoxicillin loaded chitosan-alginate polyelectrolyte complex nanoparticles as mucopenetrating delivery system for h. Pylori. | Sci Pharm | pmid:21886911 | |
| Kobler E et al. | [Effectiveness of short-term triple therapy for healing Helicobacter pylori infection in ulcer disease]. | 1997 | Schweiz Med Wochenschr Suppl | pmid:9289833 |
| Sieber CC et al. | [Helicobacter pylori resistance against metronidazole in Switzerland: implications for eradication therapy?]. | 1994 | Schweiz Med Wochenschr | pmid:8091165 |
| Lõivukene K et al. | Metronidazole and clarithromycin susceptibility and the subtypes of vacA of Helicobacter pylori isolates in Estonia. | 2000 | Scand. J. Infect. Dis. | pmid:10716079 |
| Edlund C et al. | Comparative effects of moxifloxacin and clarithromycin on the normal intestinal microflora. | 2000 | Scand. J. Infect. Dis. | pmid:10716083 |
| Dionisio D et al. | Encephalitis caused directly by Mycoplasma pneumoniae. | 1999 | Scand. J. Infect. Dis. | pmid:10576133 |
| Hakawi AM and Alrajhi AA | Septic arthritis due to Mycobacterium szulgai in a patient with human immunodeficiency virus: case report. | 2005 | Scand. J. Infect. Dis. | pmid:15849060 |
| Barzilai A et al. | Successful treatment of disseminated Mycobacterium simiae infection in AIDS patients. | 1998 | Scand. J. Infect. Dis. | pmid:9730300 |
| Davies BS et al. | Non-tuberculous slow-growing mycobacterial pulmonary infections in non-HIV-infected patients in south London. | 2012 | Scand. J. Infect. Dis. | pmid:23078529 |
| Inoue H et al. | Modulation of the human interleukin-12p40 response by a triazole antifungal derivative, itraconazole. | 2004 | Scand. J. Infect. Dis. | pmid:15370674 |
| Kiiveri KM et al. | Recurrent endocarditis caused by beta-haemolytic streptococci group B. | 2004 | Scand. J. Infect. Dis. | pmid:15307575 |
| Jakobsson H et al. | Macrolide resistance in the normal microbiota after Helicobacter pylori treatment. | 2007 | Scand. J. Infect. Dis. | pmid:17701712 |
| Cordtz J and Jensen JS | Disseminated Ureaplasma urealyticum infection in a hypo-gammaglobulinaemic renal transplant patient. | 2006 | Scand. J. Infect. Dis. | pmid:17148091 |
| Bodasing N and Kennedy D | Moraxella catarrhalis bacteraemia associated with Mycoplasma pneumoniae infection and pneumonia. | 2002 | Scand. J. Infect. Dis. | pmid:12578160 |
| Giamarellos-Bourboulis E et al. | Clarithromycin: immunomodulatory therapy of experimental sepsis and acute pyelonephritis by Escherichia coli. | 2005 | Scand. J. Infect. Dis. | pmid:15764190 |
| Burkhardt O et al. | Single- and multiple-dose pharmacokinetics of oral moxifloxacin and clarithromycin, and concentrations in serum, saliva and faeces. | 2002 | Scand. J. Infect. Dis. | pmid:12587622 |
| Ghebremichael S et al. | Antimycobacterial synergism of clarithromycin and rifabutin. | 1996 | Scand. J. Infect. Dis. | pmid:8893404 |
| Nakamura S et al. | Community acquired pneumonia (CAP) caused by Cryptococcus neoformans in a healthy individual. | 2005 | Scand. J. Infect. Dis. | pmid:16308237 |
| Trübel HK et al. | Complicated nosocomial pneumonia due to Legionella pneumophila in an immunocompromised child. | 2002 | Scand. J. Infect. Dis. | pmid:12030402 |
| Alfakry H et al. | Periodontopathogen- and host-derived immune response in acute coronary syndrome. | 2011 | Scand. J. Immunol. | pmid:21645027 |
| Alfakry H et al. | The association of serum neutrophil markers and acute coronary syndrome. | 2012 | Scand. J. Immunol. | pmid:22537345 |
| Götz JM et al. | Triple therapy with ranitidine, clarithromycin, and metronidazole in the treatment of Helicobacter pylori. | 1995 | Scand. J. Gastroenterol. Suppl. | pmid:8578230 |
| Williamson R et al. | New options in Helicobacter pylori eradication: efficacy, resistance and synergy. | 1998 | Scand. J. Gastroenterol. Suppl. | pmid:9515751 |
| Unge P | Review of Helicobacter pylori eradication regimens. | 1996 | Scand. J. Gastroenterol. Suppl. | pmid:8722388 |
| Bazzoli F | Italian omeprazole triple therapy--a 1-week regimen. | 1996 | Scand. J. Gastroenterol. Suppl. | pmid:8722395 |
| Valooran GJ et al. | Sequential therapy versus standard triple drug therapy for eradication of Helicobacter pylori in patients with perforated duodenal ulcer following simple closure. | 2011 | Scand. J. Gastroenterol. | pmid:21627398 |
| de Boer WA and Tytgat GN | The best therapy for Helicobacter pylori infection: should efficacy or side-effect profile determine our choice? | 1995 | Scand. J. Gastroenterol. | pmid:7638563 |
| Seppälä K et al. | Cure of Helicobacter pylori infection in all compliant patients: report on 644 subjects. | 2008 | Scand. J. Gastroenterol. | pmid:18609180 |
| Abut E et al. | Effect of the mucolytic erdosteine on the success rate of PPI-based first-line triple therapy for Helicobacter pylori eradication: a prospective, double-blind, randomized, placebo-controlled study. | 2010 | Scand. J. Gastroenterol. | pmid:20334478 |
| Doorakkers E et al. | Helicobacter pylori eradication in the Swedish population. | Scand. J. Gastroenterol. | pmid:28323552 | |
| Ribaldone DG et al. | Helicobacter pylori eradication: poor medical compliance from East to West of the world. | 2018 | Scand. J. Gastroenterol. | pmid:29383955 |
| Farup PG et al. | Comparison of three triple regimens with omeprazole or ranitidine bismuth citrate for Helicobacter pylori eradication. | 2002 | Scand. J. Gastroenterol. | pmid:12523585 |